Aspire Biopharma Holdings, Inc.
ASBP
$0.4871
-$0.0205-4.04%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -243.60K | -163.90K | -163.90K | -76.80K | -65.50K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | -- | -- |
| Change in Net Operating Assets | -290.20K | 58.40K | 58.40K | 418.10K | -236.80K |
| Cash from Operations | -533.80K | -105.50K | -105.50K | 341.30K | -302.30K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 38.30K | -19.10K | -19.10K | -75.90K | 38.30K |
| Cash from Investing | 38.30K | -19.10K | -19.10K | -75.90K | 38.30K |
| Total Debt Issued | 492.50K | -- | -- | -268.80K | 268.80K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 128.80K | 128.80K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 492.50K | 128.80K | 128.80K | -268.80K | 268.80K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.10K | 4.20K | 4.20K | -3.40K | 4.80K |